PDE4A, phosphodiesterase 4A, 5141

N. diseases: 168; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease BEFREE Deficiency of phosphodiesterase 4A (PDE4A), an enzyme that degrades cAMP and modulates stimulatory regulative G protein (Gs)-coupled G protein-coupled receptor signaling, protected animals either from genetic- or dietary-induced depression phenotype. 31076569 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease BEFREE Phosphodiesterase 4 (PDE4) inhibitors with potential activities for CNS disorders provide a new therapeutic strategy for depression. 30588755 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease BEFREE PDE4 cyclic nucleotide phosphodiesterases regulate 3', 5' cAMP abundance in the CNS and thereby regulate PKA activity and phosphorylation of CREB, which has been implicated in learning and memory, depression and other functions. 29197324 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease BEFREE These results provide the first demonstration for that PDE4 plays a role in modulating the development of negative emotional reactions associated with ethanol abstinence, including anxiety and depression. 28748375 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 GeneticVariation disease BEFREE These data suggest that long-form PDE4Ds, at least PDE4D4 and PDE4D5, may be the promising targets for the development of PDE4 variant-selective inhibitors as the new pharmacotherapies for depressive disorders and neurodegenerative diseases involving memory deficits. 23003922 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease PSYGENET These data suggest that long-form PDE4Ds, at least PDE4D4 and PDE4D5, may be the promising targets for the development of PDE4 variant-selective inhibitors as the new pharmacotherapies for depressive disorders and neurodegenerative diseases involving memory deficits. 23003922 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease PSYGENET The Pde4 family has been implicated in depression and cognition, and PDE4 inhibitors have been evaluated as antidepressants and possible cognitive enhancers. 22487514 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease PSYGENET Phosphodiesterase-4 (PDE4), an enzyme that catalyzes the hydrolysis of cyclic AMP and plays a critical role in controlling its intracellular concentration, has been implicated in depression- and anxiety-like behaviors. 17700644 2008
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease PSYGENET PDE4 has been reported to be involved in various central nervous system (CNS) functions including depression, memory, and schizophrenia, although the specific subtype mediating these effects remains unclear. 18060387 2008
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease PSYGENET The cyclic adenosine monophosphate-specific phosphodiesterase-4 (PDE4) gene family is the target of several potential therapeutic inhibitors and the PDE4B gene has been associated with schizophrenia and depression. 18090323 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 GeneticVariation disease BEFREE Q31L mutants had lower PDE4B activity, consistent with their resistance to rolipram, suggesting decreased PDE4 activity as a contributory factor in depression. 17481393 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.370 Biomarker disease BEFREE The cyclic adenosine monophosphate-specific phosphodiesterase-4 (PDE4) gene family is the target of several potential therapeutic inhibitors and the PDE4B gene has been associated with schizophrenia and depression. 18090323 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease BEFREE Phosphodiesterase 4 (PDE4) inhibitors with potential activities for CNS disorders provide a new therapeutic strategy for depression. 30588755 2019
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease BEFREE Deficiency of phosphodiesterase 4A (PDE4A), an enzyme that degrades cAMP and modulates stimulatory regulative G protein (Gs)-coupled G protein-coupled receptor signaling, protected animals either from genetic- or dietary-induced depression phenotype. 31076569 2019
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease BEFREE These results provide the first demonstration for that PDE4 plays a role in modulating the development of negative emotional reactions associated with ethanol abstinence, including anxiety and depression. 28748375 2017
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease BEFREE PDE4 cyclic nucleotide phosphodiesterases regulate 3', 5' cAMP abundance in the CNS and thereby regulate PKA activity and phosphorylation of CREB, which has been implicated in learning and memory, depression and other functions. 29197324 2017
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease PSYGENET The Pde4 family has been implicated in depression and cognition, and PDE4 inhibitors have been evaluated as antidepressants and possible cognitive enhancers. 22487514 2012
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease PSYGENET Phosphodiesterase-4 (PDE4), an enzyme that catalyzes the hydrolysis of cyclic AMP and plays a critical role in controlling its intracellular concentration, has been implicated in depression- and anxiety-like behaviors. 17700644 2008
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease PSYGENET PDE4 has been reported to be involved in various central nervous system (CNS) functions including depression, memory, and schizophrenia, although the specific subtype mediating these effects remains unclear. 18060387 2008
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease PSYGENET Q31L mutants had lower PDE4B activity, consistent with their resistance to rolipram, suggesting decreased PDE4 activity as a contributory factor in depression. 17481393 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 GeneticVariation disease BEFREE Q31L mutants had lower PDE4B activity, consistent with their resistance to rolipram, suggesting decreased PDE4 activity as a contributory factor in depression. 17481393 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease BEFREE The cyclic adenosine monophosphate-specific phosphodiesterase-4 (PDE4) gene family is the target of several potential therapeutic inhibitors and the PDE4B gene has been associated with schizophrenia and depression. 18090323 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.360 Biomarker disease PSYGENET The cyclic adenosine monophosphate-specific phosphodiesterase-4 (PDE4) gene family is the target of several potential therapeutic inhibitors and the PDE4B gene has been associated with schizophrenia and depression. 18090323 2007
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.350 Biomarker disease BEFREE Results support the mechanistic validation of potential novel strategies for improving cognitive dysfunction in schizophrenia and suggest that PDE4 inhibition may be beneficial for cognitive dysfunction in schizophrenia. 30536081 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.350 Biomarker disease PSYGENET These results indicate that PDE4A and PLAT may be susceptibility genes for schizophrenia in the Japanese population. 21898905 2011